ArticlePharmacology research & perspectives2026
Impacts of a Statewide Prescription Drug Monitoring Program-Healthcare Practitioner Perspectives.
Article in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study examined the perceived impacts of New South Wales' (NSW) statewide prescription drug monitoring program (PDMP; "SafeScript NSW") from the perspective of prescribers and pharmacists, using a qualitative descriptive design. Fourteen prescribers and pharmacists who were users of NSW's PDMP completed semi-structured interviews between May and August 2024. Thematic analysis was guided by the Quadruple Aim framework. Impacts were classified as those relating to (1) population health outcomes, (2) patients' care experience, (3) costs, (4) practitioners' work experience. PDMP's perceived impacts on population health included improved medication safety and reduced prescription shopping. Key patient impacts included risk of stigma and treatment interruption. Despite these, both prescribers and pharmacists reported improved therapeutic relationships with patients following SafeScript NSW use. Impacts on relationships between healthcare practitioners were mixed, with resistance encountered from those who do not use SafeScript NSW. No impacts of PDMP on healthcare delivery costs were reported. Participants discussed efficiency impacts relating to practitioners' work. Both practitioner groups reported PDMP use increased confidence and safer prescribing/dispensing practices. Workflow misalignment and workarounds were reported, predominantly by pharmacists. This study adds evidence on healthcare practitioners' perspectives on PDMP. To minimize negative impacts, we suggest further evaluation and strategies to address user-identified gaps, including workflow challenges. Collaborative development of system improvements and strategies with users can maximize continued user acceptance and uptake, benefits realization, and the system's long-term success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.